DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: arformoterol tartrate

Summary for Generic Name: arformoterol tartrate

Tradenames:1
Patents:13
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list1
Therapeutic Class:Respiratory Tract Agents

Pharmacology for Ingredient: arformoterol tartrate

Clinical Trials for: arformoterol tartrate

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: COPD

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: COPD

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)
Status: Withdrawn Condition: Chronic Obstructive Pulmonary Disease; COPD; Chronic Bronchitis; Emphysema

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: Chronic Obstructive Pulmonary Disease; Bronchitis; Emphysema

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: Chronic Obstructive Pulmonary Disease (COPD)

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
Status: Completed Condition: Chronic Obstructive Pulmonary Disease; Bronchitis; Emphysema

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: COPD

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
Status: Terminated Condition: Acute Asthma

Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
Status: Completed Condition: Stable Asthma

Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
Status: Recruiting Condition: Chronic Obstructive Pulmonary Disease; COPD; Emphysema; Chronic Bronchitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes7,145,036<disabled>Y
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes6,472,563<disabled>Y
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes6,720,453<disabled>Y
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes7,465,756<disabled>Y
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc